Digitalization in pharmaceutical industry: What to focus on under the digital implementation process?

Abstract

Digitalization of any manufacture industry is a key step in any progress of the production process. The process of digitalization includes both increased use of robotics, automatization solutions and computerization, thereby allowing to reduce costs, to improve efficiency and productivity, and to be flexible to changes. Pharmaceutical Industry (PI) has however been resistant to digitalization, mainly due to fair experience and complexity of the entailed development and manufacture processes. Nevertheless, there is a clear need to digitalize PI as the demand in both traditional and new drugs is constantly growing. Contract Development Manufacture Organizations (CDMOs) have a special digitalizing challenge. Digitalization of PI, and CDMO precisely, should be tightly related to the main aspects of Good Manufacture Practice (GMP), and, to succeed in PI digitalizing requires constant focus on GMP. Close collaboration with constantly changing stakeholders is another important factor which should be in focus during digitalization of CDMO. This paper represents an overview over the main aspects of CDMO digitalization and discusses both the opportunities and challenges of the process, focusing on the practical solutions for successive digital implementation.

Can environmental regulations and R&D subsidies promote GTFP in pharmaceutical industry? Evidence from Chinese provincial panel data

“…Further, Column (2) shows the results of model (7). There is also a U-shaped relationship between environmental regulations and the pharmaceutical industry's GTFP.…”

“…The demand for pharmaceutical products will gradually expand over the future years as the global population ages and health management knowledge rises ( 1 ). Hole et al ( 2 ) point out that the pharmaceutical industry is one of the fastest-growing economic sectors with worldwide revenue. In recent years, due to increasing concerns on public health, China's pharmaceutical industry has made great progress, the scale of the industry has grown rapidly, the supply capacity has been significantly enhanced, and it occupies an important position in the national economy 1 .…”

Factors influencing the creation of an industry 4.0 strategy in the generic pharmaceutical industry

“…There is an expectation from regulatory authorities that firms to demonstrate data integrity and process control via the digitalization of manufacturing and laboratory processes. 54 However, there was a counter finding that in the generic pharmaceutical industry Regulatory Compliance requirements can be a barrier to creating a I4.0 due to the complexity and costs involved with implementation and re-validation of processes. These paradoxical findings align with Arden et al 6 that note "most regulations were developed in an Industry 2.0 paradigm of traditional batch manufacturing" and that "changes in the regulatory structure to enable new technologies" are needed to encourage I4.0 adoption As per the definitions of digital transformation found in the SLR by Kraus et al 12 ; to transform the industry, changes that take the view of the customer and consumers as well as overall industry efficiency and quality into account are needed to drive I4.0 strategy.…”

The Significance of Digitalisation and Artificial Intelligence in The Healthcare Sector: A Review

“…Virtualisation started with the fourth industrial revolution and became the basis of industry and workflow. The main reasons, such as the increase in the population, the increase in health needs and the increase in health literacy, led to a focus on growing the health sector and introducing digitisation and artificial intelligence in it [41][42][43][44][45][46]. Although the health sector was lingering behind the rest of the sectors in applying artificial intelligence, it quickly adapted to artificial intelligence and electronic digitisation [47][48][49][50].…”